JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders-Reference-Cited by-同舟云学术

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders

Published:2006 Issue:9 Volume:107 Page:2206-2211
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Rumi Elisa,Passamonti Francesco,Pietra Daniela,Porta Matteo G. Della,Arcaini Luca,Boggi Sabrina,Elena Chiara,Boveri Emanuela,Pascutto Cristiana,Lazzarino Mario,Cazzola Mario

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference32 articles.

1. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

2. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

3. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

4. A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders

5. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Logical modelling of myelofibrotic microenvironment predicts dysregulated progenitor stem cell crosstalk;Biosystems;2023-09

2. Logical modelling of myelofibrotic microenvironment predicts dysregulated progenitor stem cell crosstalk;2022-12-14

3. A novel start‐loss mutation of the SH2B3 gene in a family with myeloproliferative neoplasms;Hematological Oncology;2022-05-21

4. Janus Kinase-2 V617F Mutation and Antiphospholipid Syndrome in Cerebral Sinus Venous Thrombosis: Natural History and Retrospective Bicenter Analysis;Frontiers in Neurology;2022-04-14

5. Germline Predisposition in the Field of Myeloproliferative Neoplasms;Interdisciplinary Cancer Research;2022